Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence

Radiation Oncology

Volumn 9, Issue 1, 2014, Pages

  Decaestecker, Karel ^a   De Meerleer, Gert ^a   Lambert, Bieke ^a   Delrue, Louke ^a   Fonteyne, Valérie ^a   Claeys, Tom ^a   De Vos, Filip ^b   Huysse, Wouter ^a   Hautekiet, Arne ^a   Maes, Gaethan ^a   Ost, Piet ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

Oligometastases; Prostate cancer; Recurrence; Salvage therapy; Stereotactic body radiotherapy

Indexed keywords

ANTIANDROGEN; ESTROGEN; FLUORODEOXYGLUCOSE F 18; GONADORELIN ANTAGONIST; GONADORELIN DERIVATIVE; PROSTATE SPECIFIC ANTIGEN;

ADULT; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE METASTASIS; BONE PAIN; CANCER CONTROL; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED RADIOTHERAPY; CONE BEAM COMPUTED TOMOGRAPHY SCANNER; DIARRHEA; FATIGUE; FOLLOW UP; FRACTURE; HUMAN; ILIAC BONE; INTENSITY MODULATED RADIATION THERAPY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; METASTASIS FREE SURVIVAL; MIDDLE AGED; OUTCOME ASSESSMENT; PELVIS LYMPH NODE; PREDICTOR VARIABLE; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE FRACTIONATION; RADIATION INJURY; REPEAT PROCEDURE; STEREOTACTIC BODY RADIATION THERAPY; TUMOR GROWTH; URINE INCONTINENCE; VISCERAL METASTASIS; BONE NEOPLASMS; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; MORTALITY; MULTIMODALITY CANCER THERAPY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROSPECTIVE STUDY; PROSTATIC NEOPLASMS; RADIATION DOSE; RADIOSURGERY; REOPERATION; SECONDARY; SURVIVAL RATE;

BONE NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RADIOSURGERY; RADIOTHERAPY DOSAGE; REOPERATION; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84902961552     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-9-135     Document Type: Article

References (30)

1. Palmbos PL, Hussain M. Non-castrate metastatic prostate cancer: have the treatment options changed?. Semin Oncol 2013, 40:337-346. 10.1053/j.seminoncol.2013.04.007, 23806498.
2. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014, 65:467-479. 10.1016/j.eururo.2013.11.002, 24321502.
3. Abrahamsson PA. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Eur Urol 2010, 57:49-59. 10.1016/j.eururo.2009.07.049, 19683858.
4. Taylor LG, Canfield SE, Du XL. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer 2009, 115:2388-2399. 10.1002/cncr.24283, 19399748.
5. Schweizer MT, Zhou XC, Wang H, Yang T, Shaukat F, Partin AW, Eisenberger MA, Antonarakis ES. Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy. Annals of Oncol 2013, 24:2881-2886.
6. Ost P, Decaestecker K, Lambert B, Fonteyne V, Delrue L, Lumen N, Ameye F, De Meerleer G. Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer. Prostate 2014, 74:297-305. 10.1002/pros.22750, 24395565.
7. Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol 2011, 8:378-382.
8. Tree AC, Khoo VS, Eeles RA, Ahmed M, Dearnaley DP, Hawkins MA, Huddart RA, Nutting CM, Ostler PJ, van As NJ. Stereotactic body radiotherapy for oligometastases. Lancet Oncol 2013, 14:e28-e37. 10.1016/S1470-2045(12)70510-7, 23276369.
9. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, Van der Kwast T, Wiegel T, Zattoni F, Heidenreich A. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011, 59:572-583. 10.1016/j.eururo.2011.01.025, 21315502.
10. Jadvar H. Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline. J Nucl Med 2011, 52:81-89. 10.2967/jnumed.110.077941, 3012154, 21149473.
11. De Visschere PJ, De Meerleer GO, Futterer JJ, Villeirs GM. Role of MRI in follow-up after focal therapy for prostate carcinoma. AJR Am J Roentgenol 2010, 194:1427-1433. 10.2214/AJR.10.4263, 20489080.
12. Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G, Rouviere O, Logager V, Futterer JJ, . European Society of Urogenital R ESUR prostate MR guidelines 2012. Eur Radiol 2012, 22:746-757. 10.1007/s00330-011-2377-y, 3297750, 22322308, European Society of Urogenital R.
13. Berkovic P, De Meerleer G, Delrue L, Lambert B, Fonteyne V, Lumen N, Decaestecker K, Villeirs G, Vuye P, Ost P. Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy. Clin Genitourin Cancer 2013, 11:27-32. 10.1016/j.clgc.2012.08.003, 23010414.
14. Brown JM, Carlson DJ, Brenner DJ. The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved?. Int J Radiat Oncol Biol Phys 2014, 88:254-262. 10.1016/j.ijrobp.2013.07.022, 24411596.
15. Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, Keall P, Lovelock M, Meeks S, Papiez L, Purdie T, Sadagopan R, Schell MC, Salter B, Schlesinger DJ, Shiu AS, Solberg T, Song DY, Stieber V, Timmerman R, Tome WA, Verellen D, Wang L, Yin FF. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys 2010, 37:4078-4101. 10.1118/1.3438081, 20879569.
16. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN Rubin P. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003, 13(3):176-181. 10.1016/S1053-4296(03)00031-6, 12903007.
17. Yossepowitch O, Bianco FJ, Eggener SE, Eastham JA, Scher HI, Scardino PT. The natural history of noncastrate metastatic prostate cancer after radical prostatectomy. Eur Urol 2007, 51:940-947. discussion 947-948, 10.1016/j.eururo.2006.10.045, 2646889, 17125912.
18. Singh D, Yi WS, Brasacchio RA, Muhs AG, Smudzin T, Williams JP, Messing E, Okunieff P. Is there a favorable subset of patients with prostate cancer who develop oligometastases?. Int J Radiat Oncol Biol Phys 2004, 58:3-10. 10.1016/S0360-3016(03)01442-1, 14697414.
19. Pasoglou V, Larbi A, Collette L, Annet L, Jamar F, Machiels JP, Michoux N, Berg BC, Tombal B, Lecouvet FE. One-step TNM staging of high-risk prostate cancer using magnetic resonance imaging (MRI): Toward an upfront simplified " all-in-one" imaging approach?. Prostate 2014, 74:469-477. 10.1002/pros.22764, 24375774.
20. Richter JA, Rodriguez M, Rioja J, Penuelas I, Marti-Climent J, Garrastachu P, Quincoces G, Zudaire J, Garcia-Velloso MJ. Dual tracer 11C-choline and FDG-PET in the diagnosis of biochemical prostate cancer relapse after radical treatment. Mol Imaging Biol 2010, 12:210-217. 10.1007/s11307-009-0243-y, 19543774.
21. Tilki D, Reich O, Graser A, Hacker M, Silchinger J, Becker AJ, Khoder W, Bartenstein P, Stief CG, Loidl W, Seitz M. 18F-Fluoroethylcholine PET/CT identifies lymph node metastasis in patients with prostate-specific antigen failure after radical prostatectomy but underestimates its extent. Eur Urol 2013, 63:792-796. 10.1016/j.eururo.2012.08.003, 22902037.
22. Casamassima F, Masi L, Menichelli C, Bonucci I, Casamassima E, Lazzeri M, Gulisano M, Aterini S. Efficacy of eradicative radiotherapy for limited nodal metastases detected with choline PET scan in prostate cancer patients. Tumori 2011, 97:49-55.
23. Schick U, Jorcano S, Nouet P, Rouzaud M, Vees H, Zilli T, Ratib O, Weber DC, Miralbell R. Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases. Acta Oncol 2013, 52:1622-1628. 10.3109/0284186X.2013.764010, 23544357.
24. Picchio M, Berardi G, Fodor A, Busnardo E, Crivellaro C, Giovacchini G, Fiorino C, Kirienko M, Incerti E, Messa C, Gianolli L, Di Muzio N. C-Choline PET/CT as a guide to radiation treatment planning of lymph-node relapses in prostate cancer patients. Eur J Nucl Med Mol Imaging 2014, doi:10.1007/s00259-014-2734-6.
25. Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, Holland-Letz T, Hadaschik BA, Giesel FL, Debus J, Haberkorn U. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2014, 41:11-20. 10.1007/s00259-013-2525-5, 3843747, 24072344.
26. Birkhauser FD, Studer UE, Froehlich JM, Triantafyllou M, Bains LJ, Petralia G, Vermathen P, Fleischmann A, Thoeny HC. Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging facilitates detection of metastases in normal-sized pelvic lymph nodes of patients with bladder and prostate cancer. Eur Urol 2013, 64:953-960. 10.1016/j.eururo.2013.07.032, 23916692.
27. Muacevic A, Kufeld M, Rist C, Wowra B, Stief C, Staehler M. Safety and feasibility of image-guided robotic radiosurgery for patients with limited bone metastases of prostate cancer. Urol Oncol 2011, 31(4):455-460.
28. Ahmed KA, Barney BM, Davis BJ, Park SS, Kwon ED, Olivier KR. Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer. Front Oncol 2012, 2:215. 3551203, 23346551.
29. Jereczek-Fossa BA, Beltramo G, Fariselli L, Fodor C, Santoro L, Vavassori A, Zerini D, Gherardi F, Ascione C, Bossi-Zanetti I, Mauro R, Bregantin A, Bianchi LC, De Cobelli O, Orecchia R. Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer. Int J Radiat Oncol Biol Phys 2012, 82:889-897. 10.1016/j.ijrobp.2010.11.031, 21277113.
30. Pai HH, Pickles T, Keyes M, Jones S, McDonald RE, Lesperance M, Berthelet E. Randomized study evaluating testosterone recovery using short-versus long-acting luteinizing hormone releasing hormone agonists. Can Urol Assoc J 2011, 5:173-179. 10.5489/cuaj.10102, 3114026, 21672478.